Malignant hyperthermia

Czech version

Authors: T. Vymazal
Authors‘ workplace: Klinika anesteziologie, resuscitace a intenzivní medicíny, 2. LF UK a FN v Motole, Praha
Published in: Anest. intenziv. Med., 27, 2016, č. 2, s. 71-74
Category: Anesthesiology - Review Article

Overview

Malignant hyperthermia is a rare, life-threatening condition, usually triggered by exposure to certain drugs used for general anaesthesia – specifically volatile anaesthetics (halothane, isoflurane, sevoflurane) and neuromuscular blocking agents (esp. suxamethonium). In susceptible individuals, these drugs can induce a drastic and uncontrolled increase in oxidative metabolism in the skeletal muscle leading to muscle rigidity, which overwhelms the body’s capacity to supply oxygen, remove carbon dioxide and regulate body temperature, eventually leading to circulatory collapse and death if not immediately treated. This review article brings information about the pathophysiology, symptoms, treatment and prevention of malignant hyperthermia for a wide range of clinicians.

Keywords:
malignant hyperthermia – general anaesthesia

Sources

1. Harrison’s Principles of Internal Medicine. 2008, p. 18, 419–20.

2. Civetta, Taylor & Kirby’s Critical Care. 2009, p. 1100–1101, 1331–1334.

3. David E: Longnecker. Anestesiology. 2008. p. 1964–1984.

4. Johannsen, S., Treves, S., Müller, C. R., Mögele, S., Schneiderbanger, D., Roewer, N., Schuster, F. Functional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia. Neuromuscul. Disord., 2015, Nov 11. pii: S0960-8966(15)00770-1. doi: 10.1016/j.nmd.2015.11.001. [Epub ahead of print].

5. Miyamoto, Y., Miyashita, T., Takaki, S,, Goto, T. Perioperative considerations in adult mitochondrial disease: A case series and a review of 111 cases. Mitochondrion., 2015, Nov 19, 26, p. 26–32.

6. Campion, G. H., Hadi, A. S., Berman, A. J., Hoffman, R. S. Questions regarding the diagnosis of malignant hyperthermia. Anesthesiology, 2015, 123, 3, p. 731–732. doi: 10.1097/ALN.0000000000000760.

7. Petersen, B., Busch, T., Meinecke, C. D., Börge, B., Kluba, K., Kaisers, U. X., Rüffert, H. Telephone enquiries on the topic of malignant hyperthermia : Evaluation of the content and subsequent diagnostic results at the MH Center Leipzig. Anaesthesist, 2015, Oct 19. [Epub ahead of print].

8. Isaak, R. S., Stiegler, M. P. Review of crisis resource management (CRM) principles in the setting of intraoperative malignant hyperthermia. J. Anesth., 2015, Dec 17. [Epub ahead of print].

9. Lu, Z., Rosenberg, H., Brady, J. E., Li, G. Prevalence of Malignant Hyperthermia Diagnosis in New York State Ambulatory Surgery Center Discharge Records 2002 to 2011. Anesth. Analg. 2015, Nov 9. [Epub ahead of print].

10. http://www.mhaus.org/

11. http://www.hypertermie.estranky.cz/

12. http://www.mhinfo.cz/info/

Labels

Anaesthesiology, Resuscitation and Inten Intensive Care Medicine

The role of antithrombin and thromboelastography in the management of early disseminated intravascular coagulopathy following peripartum hysterectomy

Current opinion on caudal epidural blockade and its complications in children

Sleep disturbances in perioperative and ICU patients – review

Alarmins and their role in perioperative medicine

Intravenous fluid therapy in intensive care

Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration: An Updated Report by the American Society of Anesthesiologists Task Force on Neuraxial Opioids and the American Society of Regional Anesthesia and Pain Medicine

The Spireta Project

Article was published in

Anaesthesiology and Intensive Care Medicine

2016 Issue 2